SUPN Supernus Pharmaceuticals Inc.

Supernus to Present at the Wells Fargo Virtual Health Care Conference

Supernus to Present at the Wells Fargo Virtual Health Care Conference

ROCKVILLE, Md., Sept. 02, 2020 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company's management will present an overview and update, as well as host investor meetings, at the Wells Fargo 2020 Virtual Healthcare Conference on Wednesday, September 9, 2020 at 9:20 a.m. ET. 

Investors interested in arranging a virtual meeting with the Company's management during this conference should contact the conference coordinator.

A live webcast of the presentation can be accessed by visiting in the Investor Relations section on the Company's website at . An archived replay of this webcast will be available for 60 days on the Company's website after the conference.

About Supernus Pharmaceuticals, Inc.

Supernus Pharmaceuticals, Inc. is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The Company markets Trokendi XR® (extended-release topiramate) for the prophylaxis of migraine and the treatment of epilepsy; Oxtellar XR® (extended-release oxcarbazepine) for the treatment of epilepsy; APOKYN® (apomorphine hydrochloride injection) for the acute treatment of hypomobility in advanced Parkinson’s disease (PD); MYOBLOC® (rimabotulinumtoxinB) for the treatment of cervical dystonia and treatment of chronic sialorrhea in adults; and XADAGO® (safinamide) as an adjunctive treatment to levodopa/carbidopa in PD patients with hypomobility. The Company is also developing several product candidates to address large market opportunities in the CNS market, including SPN-812 for the treatment of ADHD; apomorphine infusion pump for hypomobility in PD; SPN-820 for treatment-resistant depression; and SPN-817 for the treatment of epilepsy.

See full Prescribing Information for our products here: , , , , and .

APOKYN Pen and the apomorphine infusion pump product candidate licensed from Britannia Pharmaceuticals Limited.

XADAGO is licensed from Zambon S.p.A.

All trademarks are the property of their respective owners.

CONTACTS:

Jack A. Khattar, President and CEO

Gregory S. Patrick, Senior Vice President and CFO

Supernus Pharmaceuticals, Inc.

Tel: (301) 838-2591

or

INVESTOR CONTACT:

Peter Vozzo

Westwicke, an ICR Company

Office: (443) 213-0505

Mobile: (443) 377-4767

Email:

EN
02/09/2020

Underlying

SUPNSupernus Pharmaceuticals Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Supernus Pharmaceuticals Inc.

 PRESS RELEASE
Free
SUPN Supernus Pharma...

Supernus Pharmaceuticals to Acquire Sage Therapeutics, Strengthening i...

Supernus Pharmaceuticals to Acquire Sage Therapeutics, Strengthening its Neuropsychiatry Product Portfolio Proposed acquisition expected to accelerate mid- to long-term revenue and cash flow growth and further diversify revenue base.Strengthens Supernus’ leading presence in neuropsychiatric conditions with an innovative commercial product, ZURZUVAE® (zuranolone), and a novel CNS discovery platform.Expected to be significantly accretive in 2026 with potential cost synergies of up to $200 million on an annual basis.Upfront cash payment of $8.50 per share, plus one non-tradable contingent valu...

June 16, 2025 1 EN
 PRESS RELEASE
Free
SUPN Supernus Pharma...

Jay Glazer and Wife Rosie Glazer Offer Candid Look at ADHD and Relatio...

Jay Glazer and Wife Rosie Glazer Offer Candid Look at ADHD and Relationships in New Qelbree® Content Series with Supernus Pharmaceuticals New video series explores the impact of ADHD on relationships and the role of Qelbree in helping Jay’s ADHD symptom management ROCKVILLE, Md., May 29, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals is expanding its partnership with TV personality and sports reporter Jay Glazer in a new content series featuring his wife, Rosie Glazer. The series, which launches its first episode on the All About ADHD YouTube channel in May for Mental Health Awarenes...

May 29, 2025 1 EN
 PRESS RELEASE
Free
SUPN Supernus Pharma...

Supernus Announces Paragraph IV ANDA Filings for Qelbree®

Supernus Announces Paragraph IV ANDA Filings for Qelbree® ROCKVILLE, Md., May 28, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company received Paragraph IV Notice Letters from third parties notifying Supernus that the third parties submitted Abbreviated New Drug Applications (ANDAs) for viloxazine extended-release capsules, eq. 100, 150, and 200 mg base. Supernus is currently reviewing the details o...

May 28, 2025 1 EN
 PRESS RELEASE
Free
SUPN Supernus Pharma...

Supernus to Participate in the 2025 Jefferies Global Healthcare Confer...

Supernus to Participate in the 2025 Jefferies Global Healthcare Conference ROCKVILLE, Md., May 28, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that Jack A. Khattar, President and CEO of Supernus Pharmaceuticals, will participate in a fireside chat at the 2025 Jefferies Global Healthcare Conference on Wednesday, June 4, 2025, at 2:00 p.m. ET in New York City. Investors interested in arranging a meeting with...

May 28, 2025 1 EN
 PRESS RELEASE
Free
SUPN Supernus Pharma...

Busy Philipps Empowers Women with ADHD to Go from Feeling Misrepresent...

Busy Philipps Empowers Women with ADHD to Go from Feeling Misrepresented to Being ‘Ms. Represented’ in First-of-its-Kind Campaign with Supernus Pharmaceuticals Females with ADHD frequently present with inattentive symptoms, which can be more difficult to recognize than the hyperactive and impulsive symptoms more often seen in malesBoys are two times more likely to be diagnosed with ADHD than girls, leaving many girls and women undiagnosed and untreatedBusy is flipping the script for women with ADHD by sharing her own diagnosis and treatment journey with Qelbree® (viloxazine extended-release...

May 20, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch